- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00772941
Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
Drug Use Investigation Of Champix (Regulatory Post Marketing Commitment Plan)
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients need to be administered Varenicline(Champix) in order to be enrolled in the surveillance.
Exclusion Criteria:
- Patients not administered Varenicline(Champix).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Varenicline
Patients taking Varenicline.
|
Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks."
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk Factors for the Frequency of Treatment Related Adverse Events - Gender.
Time Frame: 24 weeks
|
Number of participants with Treatment Related Adverse Events of Varenicline to determine whether gender is a significant risk factor.
|
24 weeks
|
Risk Factors for the Frequency of Treatment Related Adverse Events - Age.
Time Frame: 24 weeks
|
Number of participants with Treatment Related Adverse Events of Varenicline to determine whether age is a significant risk factor.
|
24 weeks
|
Risk Factors for the Frequency of Treatment Related Adverse Events - Chronic Obstructive Pulmonary Disease as a Complication.
Time Frame: 24 weeks
|
Number of participants with Treatment Related Adverse Events of Varenicline to determine whether Chronic obstructive pulmonary disease as a complication is a significant risk factor.
|
24 weeks
|
Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Drugs.
Time Frame: 24 weeks
|
Number of participants with Treatment Related Adverse Events of Varenicline to determine whether taking concomitant drugs is a significant risk factor.
|
24 weeks
|
Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Therapies.
Time Frame: 24 weeks
|
Number of participants with Treatment Related Adverse Events of Varenicline to determine whether receiving concomitant therapies is a significant risk factor.
|
24 weeks
|
Risk Factors for the Frequency of Treatment Related Adverse Events - Weight at Baseline.
Time Frame: 24 weeks
|
Number of participants with Treatment Related Adverse Events to determine whether weight at baseline is a significant risk factor.
|
24 weeks
|
Risk Factors for the Proportion of Responders - Tobacco Consumption Per Day.
Time Frame: 24 weeks
|
The primary analysis item was "the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.
|
24 weeks
|
Risk Factors for the Proportion of Responders - Prolonged Administration After 12 Weeks.
Time Frame: 24 weeks
|
The primary analysis item was "the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.
|
24 weeks
|
Risk Factors for the Proportion of Responders - Antipsychotics as a Concomitant Drug.
Time Frame: 24 weeks
|
The primary analysis item was "the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.
|
24 weeks
|
Number of Participants With Treatment Related Adverse Events.
Time Frame: 24 weeks
|
Adverse events mean all unfavorable events that occur in participants after administration of Varenicline, irrespective of causal relationship to Varenicline (including clinically problematic abnormal changes in laboratory test values).
Treatment related Adverse Events were evaluated in company with the causal relationship to Varenicline.
The safety was evaluated on the first visit after 24 weeks; however, it was evaluated on the last visit for those who had stopped visiting before 24 weeks.
|
24 weeks
|
Number of Unlisted Treatment Related Adverse Events According to Japanese Package Insert.
Time Frame: 24 weeks
|
Adverse events mean all unfavorable events that occur in participants after administration of Varenicline, irrespective of causal relationship to Varenicline (including clinically problematic abnormal changes in laboratory test values).
Numbers of Treatment Related Adverse Events were evaluated in company with the causal relationship to Varenicline.
Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.
The safety was evaluated on the first visit after 24 weeks; however, it was evaluated on the last visit for those who had stopped visiting before 24 weeks.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Continuous Abstinence Situation by 52 Weeks.
Time Frame: 52 weeks
|
Number of participants with dependence on Varenicline by 52 weeks.
Varenicline-dependent Treatment Related Adverse Events are Feeling abnormal, Feeling drunk, Feeling jittery, Disturbance in attention, Dizziness, Memory impairment, Mental impairment, Psychomotor hyperactivity, Sedation, Somnolence, Confusional state, Depersonalisation, Disorientation, Dissociation, Euphoric mood, Mood variable, Mood swings, and Hallucination.
|
52 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A3051109
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on Varenicline
-
Arizona State UniversityNational Institute on Drug Abuse (NIDA); Pfizer; University of Nevada, Reno; Los...CompletedSmoking Cessation | Withdrawal Symptoms | Tobacco DependenceUnited States
-
PfizerWithdrawn
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Addiction | Crystal Meth Addiction | Amphetamine AddictionUnited States
-
Korea University Anam HospitalCompletedHealthyKorea, Republic of
-
Butler HospitalBrown UniversityCompletedDepressive Disorder | SmokingUnited States
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
PfizerCompletedSmoking CessationUnited States, Korea, Republic of, Taiwan, Canada, Georgia, Russian Federation
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)Enrolling by invitation
-
Oyster Point Pharma, Inc.CompletedHealthy SubjectsUnited States